Drugs / DA-1229_01
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT07297940 | Dec 2025 → Jan 2026 | — | Dong-A ST Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05739916 | Mar → Apr 2023 | — | Dong-A ST Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT05739903 | Mar → Apr 2023 | — | Dong-A ST Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT05739851 | Mar → Apr 2023 | — | Dong-A ST Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT05739877 | Mar → Apr 2023 | — | Dong-A ST Co., Ltd. | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT07342062 Comparator | Jan → Feb 2026 | — | Dong-A ST Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DA-1229_01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05739916 ↗ |
| Route | Oral | “single dose administration (one tablet once a day)” NCT05739851 ↗ |